Insights
Search Results
Client Highlights
6.02.26
Wilson Sonsini Advises BVF Partners on IP Matters Related to Contraline’s $92.5 Million Series B
On June 2, 2026, Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. Wilson Sonsini Goodrich & Rosati advised BVF Partners on IP matters related to the transaction.
News Articles
5.21.26
Michael Hostetler Recognized Among Daily Journal’s 2026 Top IP Lawyers
On May 21, 2026, Wilson Sonsini partner Michael Hostetler was recognized in the Daily Journal’s special report "Top Intellectual Property Lawyers 2026," an annual list honoring California's top lawyers specializing in patent litigation, trademark, and copyright. Michael has over 25 years of experience specializing in patent law for life sciences companies, particularly in pharmaceuticals and biotechnology.
Client Highlights
5.11.26
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.
Podcasts
5.07.26
NextGen VC Podcast - Building Biotech Companies from Day One: Aimee Raleigh of Atlas Venture
What does it actually take to turn an idea into a biotech company? In the latest episode of the NextGen VC Podcast, Aimee Raleigh, Ph.D., principal at Atlas Venture, joins hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang to explore how companies get built before they’re even companies.
From evaluating early science to forming a real point of view, Aimee shares how investors build conviction at the earliest stages. She discusses the pace of early-stage venture, as well as how to juggle multiple opportunities, make decisions with imperfect data, and figure out what’s worth leaning into, among other topics. Aimee also discusses her path into venture and what she’s learned along the way in an industry that doesn’t slow down.
From evaluating early science to forming a real point of view, Aimee shares how investors build conviction at the earliest stages. She discusses the pace of early-stage venture, as well as how to juggle multiple opportunities, make decisions with imperfect data, and figure out what’s worth leaning into, among other topics. Aimee also discusses her path into venture and what she’s learned along the way in an industry that doesn’t slow down.
Client Highlights
5.04.26
Firm Advises Candid Therapeutics on Patent Matters Related to Its $2 Billion Acquisition by UCB
On May 3, 2026, UCB, a global biopharmaceutical company, announced a definitive agreement to acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers. Under the terms of the agreement, UCB will pay $2 billion in upfront payments and up to $200 million in potential future milestone payments. Wilson Sonsini Goodrich & Rosati advised Candid on patent matters related to the transaction.
Podcasts
4.09.26
NextGen VC Podcast – From Scalpel to Term Sheet: Rich Gaster of venBio
In the latest episode of the NextGen VC Podcast, Rich Gaster, M.D., Ph.D., managing partner at venBio, joins hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang to discuss what it takes to go from performing reconstructive plastic surgeries at Harvard to becoming a managing partner at one of biotech’s most focused venture firms. He traces a career path that runs through Stanford M.D.-Ph.D. training, two grad school start-ups, the company-building engine at Third Rock Ventures, and the founding team of Pliant Therapeutics before landing at venBio, where he helped engineer three back-to-back acquisitions in a single quarter.
Client Highlights
4.09.26
Wilson Sonsini Advises Forte Biosciences on $150 Million Public Offering
On April 8, 2026, Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Client Highlights
4.02.26
Wilson Sonsini Advises Frazier Life Sciences on IP Matters Related to Immutrin’s $87 Million Series A
On March 24, 2026, Immutrin, a biotechnology company developing next generation antibody therapy to reverse amyloidosis, announced it has successfully raised $87 million in a Series A financing. The round was led by new investor Frazier Life Sciences, with participation from F-Prime, Qiming Venture Partners, SR One, and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures. Wilson Sonsini Goodrich & Rosati advised Frazier Life Sciences on patent matters related to the transaction.
Client Highlights
3.31.26
Wilson Sonsini Advises Centessa on IP Matters Related to Acquisition by Lilly
On March 31, 2026, Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announced a definitive agreement for Eli Lilly and Company (Lilly), an American multinational pharmaceutical company, to acquire Centessa. Under the terms of the transaction agreement, Lilly will acquire all of the issued and to be issued share capital of Centessa (including the American Depositary Shares (ADSs) representing ordinary shares) for $38.00 in cash per share plus one non-transferrable contingent value right (CVR) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones described below, for total potential aggregate per share consideration of up to $47.00. The upfront cash consideration represents an aggregate equity value of approximately $6.3 billion and the CVR represents an additional potential aggregate equity value of approximately $1.5 billion. Wilson Sonsini Goodrich & Rosati advised Centessa in IP matters related to the transaction.
Client Highlights
3.30.26
Firm Advises Pinnacle Medicines on Corporate and IP Matters Related to Oversubscribed $89 Million Series B Financing
On March 26, 2026, Pinnacle Medicines, a biotechnology company pioneering the development of oral peptide therapeutics using proprietary AI and physics-based platforms, announced the closing of an oversubscribed $89 million Series B financing. The round was co-led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investors including OrbiMed. Wilson Sonsini Goodrich & Rosati advised Pinnacle on corporate and IP matters related to the transaction.
Podcasts
3.30.26
NextGen VC Podcast: Dr. Anna French of Qiming Venture Partners
In the latest episode of the NextGen VC Podcast, Dr. Anna French, managing partner at Qiming Venture Partners USA, joins hosts and Wilson Sonsini partners Michael Hostetler and Jennifer Fang to trace her non-linear path from an Oxford D.Phil. and Boston Consulting Group boardrooms to becoming employee No. 1 at one of biotech’s most globally connected venture firms.
Client Highlights
3.02.26
Firm Advises Candid Therapeutics on Patent Matters Related to Acquisition by Rallybio
On March 2, 2026, Rallybio and Candid Therapeutics, a global clinical-stage biotechnology company advancing a leading portfolio of T-cell engager (TCE) therapeutics for autoimmune diseases, announced that they have entered into a definitive agreement pursuant to which Rallybio will acquire Candid through a merger transaction. The combined company expects to operate under the name Candid Therapeutics and trade on Nasdaq under the ticker symbol CDRX. Wilson Sonsini Goodrich & Rosati advised Candid on patent matters related to the transaction.